Nifty
Sensex
:
:
10350.10
33516.37
51.35 (0.50%)
156.47 (0.47%)

Pharmaceuticals & Drugs

Rating :
40/99

BSE: 500087 | NSE: CIPLA

621.25
17.00 (2.81%)
21-Nov-2017 | 11:39AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 607.00
  • 624.00
  • 607.00
  • 604.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 1106616
  • 6874.85
  • 663.40
  • 480.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 48,498.58
  • 42.38
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 51,987.03
  • 0.33%
  • 3.65

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 37.26%
  • 3.19%
  • 17.7%
  • FII
  • DII
  • Others
  • 0.66%
  • 14.48%
  • 26.71%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Net Sales
4,082.41
3,751.02
8.83%
3,525.05
3,593.72
-1.91%
3,582.00
3,266.54
9.66%
3,647.21
3,106.55
17.40%
Expenses
3,278.02
3,070.31
6.77%
2,878.59
2,982.75
-3.49%
3,075.76
3,047.58
0.92%
2,969.56
2,652.84
11.94%
EBITDA
804.39
680.71
18.17%
646.46
610.97
5.81%
506.24
218.96
131.20%
677.65
453.71
49.36%
EBIDTM
19.70%
18.15%
18.34%
17.00%
14.13%
6.70%
18.58%
14.60%
Other Income
113.33
27.23
316.20%
151.38
25.20
500.71%
22.79
54.74
-58.37%
153.49
79.30
93.56%
Interest
42.02
35.16
19.51%
27.86
31.34
-11.10%
33.40
36.76
-9.14%
59.33
22.95
158.52%
Depreciation
302.22
229.18
31.87%
213.43
160.81
32.72%
632.19
141.43
347.00%
257.74
137.47
87.49%
PBT
573.48
443.60
29.28%
556.55
444.02
25.34%
-136.56
95.51
-
514.07
372.59
37.97%
Tax
137.42
71.90
91.13%
130.77
70.81
84.68%
-75.70
-3.90
-
128.27
11.97
971.60%
PAT
436.06
371.70
17.32%
425.78
373.21
14.09%
-60.86
99.41
-
385.80
360.62
6.98%
PATM
10.68%
9.91%
12.08%
10.39%
-1.70%
3.04%
10.58%
11.61%
EPS
5.25
4.41
19.05%
5.08
4.54
11.89%
-0.77
1.01
-
4.66
4.27
9.13%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
4,010.38
Net Sales Growth
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
23.69%
 
Cost Of Goods Sold
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
2,054.39
Gross Profit
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
1,955.99
GP Margin
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
48.77%
Total Expenditure
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
3,377.91
Power & Fuel Cost
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
74.69
% Of Sales
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
1.86%
Employee Cost
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
186.47
% Of Sales
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
4.65%
Manufacturing Exp.
1,704.79
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
676.85
509.42
% Of Sales
11.84%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
12.70%
General & Admin Exp.
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
221.14
% Of Sales
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
5.51%
Selling & Distn. Exp.
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
282.21
% Of Sales
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
7.04%
Miscellaneous Exp.
133.52
83.99
497.67
441.10
355.12
194.07
111.96
185.92
323.64
282.21
% Of Sales
0.93%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
1.24%
EBITDA
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
632.47
EBITDA Margin
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
15.77%
Other Income
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
354.49
339.28
Interest
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
52.23
17.52
Depreciation
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
151.79
116.26
PBT
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
837.97
Tax
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
136.93
Tax Rate
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
16.34%
PAT
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
PAT before Minority Interest
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
Minority Interest
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
17.48%
PAT Growth
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
9.98%
 
Unadjusted EPS
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70
9.92
9.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,525.42
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
3,755.17
Share Capital
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
155.46
Total Reserves
12,302.48
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
3,599.71
Non-Current Liabilities
4,513.35
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
689.60
Secured Loans
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
14.09
Unsecured Loans
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
526.36
Long Term Provisions
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
0.00
Current Liabilities
3,308.07
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
1,287.80
Trade Payables
1,571.14
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
533.51
Other Current Liabilities
923.79
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
255.44
337.48
Short Term Borrowings
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
0.00
Short Term Provisions
345.91
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
416.81
Total Liabilities
20,785.07
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57
Net Block
9,472.00
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
1,661.36
Gross Block
11,305.32
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
2,201.79
Accumulated Depreciation
1,580.49
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
540.43
Non Current Assets
11,979.00
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
1,898.51
Capital Work in Progress
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
366.32
233.12
Non Current Investment
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
1.03
4.03
Long Term Loans & Adv.
477.35
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
0.00
Other Non Current Assets
209.31
176.54
168.39
151.74
154.88
38.95
30.98
0.00
0.00
0.00
Current Assets
8,806.07
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
3,834.06
Current Investments
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
89.45
Inventories
3,485.28
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
1,120.49
Sundry Debtors
2,497.42
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
1,406.49
Cash & Bank
624.21
871.40
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Other Current Assets
1,361.77
437.05
145.60
35.50
468.31
622.17
726.59
2,537.33
1,821.13
1,137.93
Short Term Loans & Adv.
968.64
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
1,103.44
Net Current Assets
5,498.00
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
2,546.26
Total Assets
20,785.07
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,382.37
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
367.00
PBT
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
837.97
Adjustment
1,379.75
950.85
630.05
552.80
283.82
396.66
288.84
146.53
252.60
104.48
Changes in Working Capital
230.72
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
-404.47
Cash after chg. in Working capital
2,832.64
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
537.98
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
-170.98
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,312.65
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
-674.41
Net Fixed Assets
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
-562.01
Net Investments
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
23.05
Others
-393.51
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
-135.45
Cash from Financing Activity
-1,323.85
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
254.83
Net Cash Inflow / Outflow
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
-52.58
Opening Cash & Equivalents
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
79.70
132.28
Closing Cash & Equivalent
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
154.92
142.23
133.38
124.79
112.21
95.03
82.91
73.50
55.82
48.20
ROA
4.98%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
13.82%
ROE
8.73%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
20.11%
ROCE
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
22.40%
Fixed Asset Turnover
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
2.05
2.05
Receivable days
60.55
57.62
57.94
58.66
70.11
77.94
87.29
115.32
118.45
108.37
Inventory Days
90.98
100.43
106.36
93.68
92.19
96.16
97.61
98.17
91.54
93.41
Payable days
44.80
48.67
52.17
44.93
48.58
50.51
56.11
69.48
59.02
46.55
Cash Conversion Cycle
106.73
109.38
112.14
107.41
113.72
123.59
128.78
144.01
150.98
155.23
Total Debt/Equity
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
0.22
0.14
Interest Cover
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86
18.15
48.83

News Update:


  • Cipla receives final approval for generic Dacogen
    20th Nov 2017, 09:01 AM

    Dacogen and its generic equivalents had US sales of approximately $180 million for the 12-month period ending September 2017

    Read More
  • Cipla receives final approval for generic Pulmicort Respules
    17th Nov 2017, 09:02 AM

    It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age

    Read More
  • Cipla planning to enter branded formulation market in China: Report
    9th Nov 2017, 10:03 AM

    The company is planning to focus on respiratory therapeutics in the country

    Read More
  • Cipla’s Q2 consolidated net profit up 18%
    7th Nov 2017, 14:33 PM

    Total consolidated income of the company rose 11.05% at Rs 4195.74 crore for quarter under review

    Read More
  • Cipla - Quarterly Results
    7th Nov 2017, 12:00 AM

    Read More
  • Cipla’s arm receives final approval for generic Renvela Tablets
    27th Oct 2017, 09:04 AM

    Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health

    Read More
  • Cipla’s arm unveils Nicotex Nicotine patches
    22nd Aug 2017, 09:36 AM

    Nicotex Nicotine patch is a skin/transdermal patch that works on the proven principle of nicotine replacement therapy and helps in quit smoking in 12 weeks

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.